Homotaurine

Homotaurine is a homolog of taurine and a close relative of acamprosate (calcium acetylhomotaurinate), and it occurs naturally in some seaweeds and marine red algae ^[1]. Like those molecules, it interacts with inhibitory neurotransmission; 3-amino-1-propanesulfonic acid has been used experimentally as a GABAthe brain's main 'calm down' (inhibitory) signal-A receptor agonistsomething that switches a receptor on, and the taurine and homotaurine family acts on GABA-A and glycine chloride channels ^[5]. This GABAergicacting through GABA, the brain's calming signal, taurine-like activity is the basis for its historical framing as a neuromodulator, but it is not the property that made it a drug candidate ^[1].

The reason homotaurine attracted development was its anti-amyloid activity. It was originally designed as a mimetic of sulfated glycosaminoglycans intended to interfere with amyloid-beta ^[4]. Detailed molecular studies later characterized a multi-ligandany molecule that binds to a receptor enveloping mechanism: rather than binding amyloid-beta in a conventional one-to-one fashion, several homotaurine molecules surround amyloid-beta 42 monomers and engage the Lys16, Lys28, and Asp23 side chains, stabilizing the monomer and inhibiting its misfolding into soluble neurotoxic oligomers and, downstream, fibrils and plaques ^[2]. In preclinical and biophysical work it reduced oligomeric and fibrillar amyloid, and comparable anti-aggregation effects have been reproduced in synthetic brain membranes ^[1][3]. The picture is not entirely clean: at least one cellular study reported that tramiprosate can promote abnormal aggregation of the tau protein, a reminder that an agent aimed at amyloid may have unintended effects on the other pathological protein in Alzheimer's disease ^[4].

Homotaurine, given as oral tramiprosate (ALZHEMED), was tested in large phase 3 trials in mild-to-moderate Alzheimer's disease. The North American Alphase study enrolled 1,052 patients but did not meet its primary cognitive and clinical endpoints, in part because of unexplained variance and methodological confounds ^[6]. A volumetric MRI subgroup nevertheless suggested reduced hippocampal atrophy and a trend toward slower cognitive decline ^[7]. The most consequential result came from pre-specified and pooled analyses across the two phase 3 studies: benefit was concentrated in carriers of the APOE4 allele and scaled with the number of alleles, with the largest, statistically significant cognitive effect in APOE4/4 homozygotes on the higher dose, a pattern named the APOE4 gene-dose effect ^[8]. After the trials, homotaurine continued to be sold as a nutraceutical for memory (marketed as VIVIMIND), and a small observational study in amnestic mild cognitive impairment reported reduced hippocampal volume loss and better episodic memory in treated individuals ^[9].

The genotype signal, rather than the negative overall result, drove the compound's second life. Oral tramiprosate suffered from high between-subject pharmacokinetic variability and gastrointestinal side effects, so a valine-conjugated prodrugan inactive compound your body converts into the active drug, ALZ-801 (valiltramiprosate), was developed; it is rapidly converted to tramiprosate after oral dosing, delivers more consistent exposure, and improves gastrointestinal tolerability ^[10]. Both tramiprosate and its major metabolitea breakdown product your body makes from a compound, 3-sulfopropanoic acid (3-SPA), which was found to be an endogenous molecule present in human cerebrospinal fluid, are active anti-oligomer agents ^[11]. A two-year phase 2 trial of ALZ-801 in APOE4 carriers with early Alzheimer's disease reported a significant reduction in plasma p-tau181, less hippocampal atrophy relative to matched controls, and broadly stable memory, with no vasogenic brain edema (ARIA) observed ^[12][13]; pharmacokinetic analysis confirmed low variability and predominantly renal clearance ^[14]. Because APOE4/4 homozygotes show accelerated hippocampal atrophy that tracks cognitive decline, this genotype was used to enrich the pivotal program ^[15]. On that basis the confirmatory APOLLOE4 phase 3 trial was conducted specifically in APOE4/4 homozygotes with early Alzheimer's disease, positioning ALZ-801 as a potential first-in-class oral anti-amyloid-oligomer therapy ^[16][17]. Its efficacy remains unproven pending that readout; separately, interest in homotaurine as a supplement continues, including within a recent multidomain lifestyle trial in subjective cognitive decline ^[18].